Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
118864-75-8c1ccc([C@@H]2NCCc3ccccc32)cc1PRTRSEDVLBBFJZ-HNNXBMFYSA-N118864-75-8DTXSID80922796Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
This chemical does not meet GHS hazard criteria for 5.9% (1 of 17) of reports.
Warning
H302 (23.5%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 17 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Warning
Acute Tox. 4 (100%)
Acute Tox. 4 (23.5%)
VerwendenLabelled Solifenacin intermediate
Verwenden(1S)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline has been used as a lead compound for the development of drugs with dopamine β-hydroxylase inhibitory activity. In vitro studies have shown that 1-phenyl-1,2,3,4-tetrahydro-isoquinoline inhibits human serum dopamine β-hydroxylase and can be used to study the possible role of this enzyme in Parkinson's disease.